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Mesenchymal Stromal Cell-Derived
Extracellular Vesicles Attenuate
Dendritic Cell Maturation and
Function
Monica Reis, Emily Mavin, Lindsay Nicholson, Kile Green, Anne M. Dickinson and
Xiao-nong Wang*
Haematological Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
Mesenchymal stromal cells (MSCs) are potent regulators of immune responses
largely through paracrine signaling. MSC secreted extracellular vesicles (MSC-EVs) are
increasingly recognized as the key paracrine factors responsible for the biological and
therapeutic function of MSCs. We report the first comprehensive study demonstrating
the immunomodulatory effect of MSC-EVs on dendritic cell (DC) maturation and
function. MSC-EVs were isolated from MSC conditioned media using differential
ultracentrifugation. Human monocyte-derived DCs were generated in the absence or
presence of MSC-EVs (20 ug/ml) then subjected to phenotypic and functional analysis
in vitro. MSC-EV treatment impaired antigen uptake by immature DCs and halted DC
maturation resulting in reduced expression of the maturation and activation markers
CD83, CD38, and CD80, decreased secretion of pro-inflammatory cytokines IL-6 and
IL-12p70 and increased production of anti-inflammatory cytokine TGF-β. MSC-EV
treated DCs also demonstrated a diminished CCR 7 expression after LPS stimulation,
coupled with a significantly reduced ability to migrate toward the CCR7-ligand CCL21,
although they were still able to stimulate allogeneic T cell proliferation in vitro. Through
microRNA profiling we have identified 49 microRNAs, which were significantly enriched
in MSC-EVs compared to their parent MSCs. MicroRNAs with known effect on
DC maturation and functions, including miR-21-5p, miR-142-3p, miR-223-3p, and
miR-126-3p, were detected within the top 10 most enriched miRNAs in MSC-EVs, with
MiR-21-5p as the third highest expressed miRNA in MSC-EVs. In silico analysis revealed
that miR-21-5p targets the CCR7 gene for degradation. To verify these observations,
DCs were transfected with miR-21-5p mimics and analyzed for their ability to migrate
toward the CCR7-ligand CCL21 in vitro. MiR-21-5p mimic transfected DCs showed a
clear trend of reduced CCR7 expression and a significantly decreased migratory ability
toward the CCL21. Our findings suggest that MSC-EVs are able to recapitulate MSC
mediated DC modulation and MSC-EV enclosed microRNAs may represent a novel
mechanism through which MSCs modulate DC functions. As MSCs are currently used
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in clinical trials to treat numerous diseases associated with immune dysregulation, such
as graft-versus-host disease and inflammatory bowel disease, our data provide novel
evidence to inform potential future application of MSC-EVs as a cell-free therapeutic
agent.
Keywords: extracellular vesicles, mesenchymal stromal cells, immunomodulation, dendritic cells,
immunomodulation, microRNA
INTRODUCTION
Mesenchymal stromal cells (MSCs) are currently used in clinical
trials to treat a range of immune dysregulation associated
diseases (1–3). The ability to modulate a wide-range of immune
responses is a well-recognized property of MSCs, through
mechanisms largely involving secretion of paracrine factors
(4). Increasing evidence has emerged recently suggesting that
MSC-derived extracellular vesicles (MSC-EVs) are the principle
biological factors through which MSCs exert their key functions
in immunomodulation and tissue regeneration. MSC-EVs,
including exosomes and microvesicles, are a heterogeneous
population of bilipid membrane nanoparticles encapsulating
a plethora of bioactive factors, including, proteins (cytokines,
membrane receptors, growth factors and enzymes) and genetic
materials (mRNAs and microRNAs) (5). They function as key
intercellular signaling mediators to elicit biological responses
via horizontal transfer of their bioactive cargo into recipient
cells (5, 6).
Recent studies have shown MSC-EV mediated
immunomodulation by targeting T cells, B cells, and NK cells
(7–13). In vitro and in vivo studies have also shown that MSC-
EVs induce an anti-inflammatory phenotype in macrophages,
characterized by the production of anti-inflammatory cytokines
IL-10 and consequent generation of regulatory T cells (8, 14).
However, despite the pivotal role that dendritic cells (DCs)
play in initiating and regulating immune responses (15)
and the fact that DCs are a key target for MSC mediated
immunomodulation, no comprehensive study has been reported
so far to demonstrate the modulatory effect that MSC-EVs may
have on the maturation and function of DCs. Furthermore, little
is known about the mechanisms of action by which MSC-EVs
exert their immunomodulatory effect. Increasing attention has
been given to MSC-EV enclosed microRNAs for their roles
in post-transcriptional regulation of gene expression through
mRNA silencing. MSC-EV enclosed microRNAs have been
shown to play important roles in the protection of tissue damage
and promotion of tissue repair in animal models of myocardial
ischemia, acute kidney injury, and osteoarthritis (6, 16–20). To
date the potential contribution of MSC-EV enclosed microRNAs
in immunomodulation of DC function remains unknown.
In this study, we investigated whether MSC-EVs are
capable of recapitulating the previously well-established
immunomodulatory effects that MSCs have on DC maturation
and function (21, 22) by examining the phenotypic and
functional features of MSC-EV treated DCs in comparison
to their untreated counterparts, including the expression of
maturation/activation markers, the ability to uptake antigen and
stimulate allogeneic T cells, as well as the profile of cytokines
secreted by DCs and T cells stimulated with treated and
untreated DCs. MSC-EV treated DCs were further examined
for their ability to migrate via the CCR7 dependent pathway.
We also profiled the microRNAs encapsulated in MSC-EVs
and performed in silico and in vitro analysis to elucidate the
mechanism of action of MSC-EV mediated immunomodulation.
MATERIALS AND METHODS
MSC Culture and Characterization
Human bone marrow-derived MSCs were generated using
standard plastic adherence method from healthy donor
bone marrow aspirates (surplus to hematopoietic stem cell
transplantation, obtained from the Newcastle Cellular Therapy
Facility, Newcastle upon Tyne, UK). In brief, bone marrow
mononuclear cells (MNCs) were isolated by density gradient
centrifugation using LymphoprepTM (Axis-Shield). MNCs were
then plated at a density of 2 × 107 cells/flask in T-25 tissue
culture flasks in basal medium containing Dulbecco’s modified
eagle medium, 100 IU/ml penicillin, 100µg/ml streptomycin, 2
IU/ml heparin and 2mM L-glutamine (all from Sigma-Aldrich),
supplemented with 5% human platelet lysate (hPL; PLTMax,
Mill Creek Lifesciences) (23). The cells were cultured for 3 days
at 37◦C in a 5% CO2 incubator. The non-adherent cell fraction
was discarded, and fresh medium was added to the adherent
cells. Medium was refreshed every 3 days and cells were passaged
when the culture reached 70–80% confluence. MSCs at passage
3 were characterized according to the criteria described by the
International Society of Cellular Therapy (ISCT) (24) and used
in all experiments throughout this study.
MSC-EV Isolation
MSC-EVs were collected from MSC conditioned medium by
differential ultracentrifugation, as previously described (25). EV-
depleted medium was prepared by overnight ultracentrifugation
at 100,000 × g of basal medium supplemented with 10% hPL.
When passage 3 MSCs reached 90% confluence, cells were
washed twice with phosphate buffered saline (PBS, Sigma-
Aldrich) and cultured in EV-depleted medium, at a final
concentration of 5% EV-depleted hPL, for a further 48 h prior
to MSC-EV isolation. The conditioned medium was then
centrifuged at 400 × g for 5min at 4◦C to exclude detached
cells and debris. The resulting supernatant was centrifuged at
2,000 × g for 20min at 4◦C, transferred to ultracentrifuge tubes
(Beckman Coulter) and centrifuged sequentially at 10,000 × g
for 45min and at 100,000 × g for 90min at 4◦C using a 45Ti
rotor (Beckman Coulter) in a BECKMAN L8-80 ultracentrifuge
Frontiers in Immunology | www.frontiersin.org 2 November 2018 | Volume 9 | Article 2538
Reis et al. MSC-EV Mediated DC Modulation
(Beckman Coulter). The MSC-EV pellet was washed in 60ml of
PBS then re-suspended in at least 100 µl of sterile PBS and stored
at−80◦C.
MSC-EV Characterization
Collected MSC-EVs were characterized based on their
morphology, particle size and surface protein expression.
EV morphology was visualized using transmission electron
microscopy (TEM). Briefly, 5 µl of PBS suspended MSC-EVs
were adsorbed for 30 s onto a carbon-coated, glow discharged
grid. Excess liquid was removed with a filter paper (Whatmann
no. 50, Sigma-Aldrich). Samples were stained with 1% uranyl
acetate for 30 s. Excess uranyl acetate solution was removed
and the MSC-EV loaded carbon-coated grids were dried
under a lamp. Grids were examined using a Philips CM100
Compustage (FEI) transmission electron microscope and digital
images were collected using an AMTCCD camera (Deben)
housed in Electron Microscopy Research Services, Newcastle
University. The particle size and concentration were measured
by nanoparticle tracking analysis (NTA). Briefly, MSC-EV pellets
were diluted at 1:100–1:500 ratios with sterile-filtered PBS and
analyzed using a Nanosight LM10 (Malvern), as described by the
manufacturer’s protocol. Three 1-min measurements were taken
for each sample. The acquired data was processed using NTA 2.3
software (Malvern). EV surface markers CD63, CD9 and CD81
were analyzed by flow cytometry. The volume of EVs suspension
equivalent to 5 µg of protein [measured with the microBCA
protein assay kit (ThermoFisher Scientific)], were coated onto 4-
µm aldehyde/sulfate latex beads (LifeTechnologies) by overnight
incubation on a rotary wheel at RT. The reaction was stopped
by incubation with 1M glycine (Sigma-Aldrich) for 30min at
RT. The MSC-EV-bead complex was washed twice with PBS
with 0.5% fetal calf serum (FCS, Invitrogen), and incubated with
CD63 PE (H5C6), CD9 PerCPCy5.5 (M-L13) and CD81-APC
(JS-81) antibodies or corresponding isotype controls (all from
BD Biosciences) for 20min at 4◦C. Following further washes in
PBS with 0.5% fetal calf serum data was acquired using a BD
FACS Canto II cytometer and analyzed with FlowJo software
(Tree Star).
Magnetic Isolation of CD3+ T Cells and
CD14+ Monocytes
Peripheral blood mononuclear cells (PBMCs) were obtained
from healthy donors by gradient centrifugation over
LymphoprepTM. CD3+ T cells and CD14+ monocytes were
immuno-magnetically isolated by depletion of non-T cells
using the Pan T cell isolation kit (Miltenyi Biotec) and positive
selection using human CD14 microbeads (Miltenyi Biotec),
respectively. Highly purified (>90% purity) CD3+ T cells and
CD14+ monocytes were used in the subsequent experiments.
Generation of Monocyte-Derived DCs and
Co-culture With MSC-EVs
Mature and immature monocyte-derived dendritic cells (mDC
and iDC, respectively) were generated frommagnetically isolated
CD14+ monocytes (26). The cells were cultured in complete
medium (RPMI 1640 with 10% FCS, 2mM L-glutamine and 100
IU/ml penicillin, 100µg/ml streptomycin) supplemented with
IL-4 and GM-CSF (both at 50 ng/ml; Immunotools) for 7 days.
MSC-EVs at a concentration of 20µg/ml were added to the DC
generation culture on day 3, when fresh medium containing
the same concentrations of IL-4 and GM-CSF was replenished.
Mature DCs were generated by adding LPS (100 ng/ml; Sigma) to
the DC culture on day 6. The EV-treated immature and mature
DCs (iDC-EV and mDC-EV) were harvested on day 7 and used
in the subsequent experiments.
T Cell Proliferation
The influence of MSC-EVs on T cell proliferative response
was evaluated in two experimental settings. Initially MSC-EVs
were added directly into the co-cultures of CFSE labeled CD3+
T cells and allogeneic mDCs, with the co-cultures without
addedMSC-EVs as controls. Subsequently,MSC-EVswere added
into the DC generation cultures as described above. Mature
DCs, with or without previous exposure to MSC-EVs, were
co-cultured with CFSE labeled allogeneic CD3+ T cells. The
same T cell: DC ratio (10:1) was used in both experimental
settings. The amount of MSC-EVs used in both settings was
identical (20µg/ml), which was pre-determined by dose titration
(Supplementary Figure S1). This MSE-EV dose was used in
all functional analysis throughout this study. The levels of T
cell proliferation were determined by CFSE dilution using flow
cytometry on day 5 of the co-culture, with the frequency of
CFSElow cells as readout for the levels of T cell proliferation.
MSC-EV Uptake by Immune Cells
MSC-EVs were labeled with PKH26 Red Fluorescence Cell
Linker Kit (Sigma-Aldrich), following the manufacturer’s
protocol with minor modifications. Briefly, 20µg/ml of MSC-
EVs were pelleted at 100,000 × g for 90min and re-suspended
in 1ml of Diluent C to which 2 µl of PKH26 was added. Diluent
C containing PKH26 without MSC-EVs was used as a negative
control. After a 20-min incubation at RT in the dark, the reaction
was stopped with 1ml of 1% bovine serum albumin (BSA; Sigma-
Aldrich). Labeled MSC-EVs were washed twice with filtered
PBS at 100,000 × g for 90min then re-suspended in complete
medium and added to the co-culture of allogeneic CD3+ T
cells and mDCs. After 24 h of incubation at 37◦C in a 5% CO2
humidified atmosphere, the cells were washed in PBS, suspended
in serum-free RPMI 1640 and seeded onto a poly-L-lysine coated
coverslip (2 × 105 cells/coverslip). Cells were incubated for
15min at 37◦C to allow attachment to the coverslip and fixed
with 2% paraformaldehyde for 15min at RT. Cells were washed
2× with PBS and blocked with antibody diluent (PBS with 0.1%
Triton X (Sigma-Aldrich) and 0.5% BSA), for 30min at 4◦C.
The cells were then incubated overnight with mouse anti-human
CD3 antibody (1:100, BD Biosciences) at 4◦C. Coverslips were
washed 2× with PBS containing 0.1% Triton and 0.1% BSA and
incubated with the secondary antibody (goat anti-mouse Dy649,
1:300; Jackson Immunoresearch) for 2 h at 4◦C. The coverslips
were washed 2× and incubated with HLA-DR FITC (1:20, BD
Biosciences) for an additional 4 h, washed 2× and mounted
with Vectashield mounting medium containing DAPI (Vector
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Laboratories). The samples were imaged using Axioimager Z2
fluorescence microscope with axiovision software V4.8 (Zeiss).
Flow Cytometry Analysis
The staining for cell surface proteins were performed following
standard protocols by incubation of cells with pre-optimized
concentrations of antibodies at 4◦C for 20min in FACS buffer
(PBS with 2% FCS and 1mM EDTA). Flow cytometry data were
acquired on BD FACS Canto II cytometer and analyzed with
FlowJo software version X (Tree Star). Unless otherwise stated
all antibodies were supplied by BD Biosciences: CD25 APC (M-
A251) or CD25 PECy7 (2A3); CD8 APC (SK1); CD4 V500
(RPA-T4), CD3 PerCPCy5.5 (SK7), CD38 PE (HIT2); CD80 PE
(L307.4); CD83 FITC (HB15e); CD86 PECy7 (FUN-1), HLA-DR
PerCP (L243); CCR7 PECy7 (G043H7; Biolegends). Appropriate
isotypes were used as controls.
Phagocytosis Assay
The ability of immature DC to uptake antigens was assessed by
incubation of immature DCs (5 × 104) with FITC-dextran (1
mg/ml; Sigma-Aldrich) in basal media for 1 h at 37◦C including
a control incubated at 4◦C to exclude extracellular binding of
FITC-dextran. Cells were then washed three times in cold FACS
buffer and analyzed by flow cytometry.
Cytokine Quantification
The level of cytokines was quantified in the culture supernatants
collected from either DC generation cultures on day 7 or DC and
T cell co-cultures on day 5 using cytometric bead array flex kit,
according to the manufacturer’s instructions (BD Biosciences).
DC supernatants were assessed for IL-6, IL-10, IL-12p70, and
TGF-ß1 whilst DC-T cell co-culture supernatants for IL-6, IFNγ,
TNFα and IL-2. Data was acquired on a FACS Canto II and
analyzed with FCAP software (BD Biosciences).
DC Migration
DC migration was assessed as described by Anderson et al.
(27), with minor modifications (27). Briefly, migration was
measured using a transwell system (pore size 8µm, Corning
Lifesciences), mDCs (1× 105) were added in the upper chamber,
and medium, with or without CCL21 (250 ng/ml, R&D systems)
in the lower chamber. After 24 h-incubation at 37◦C migrated
mDCs in the lower chamber were harvested and counted using
a Neubauer chamber (Celeromics). Migration efficiency was
calculated from the percentage of the input cells that had
migrated. The percentage of mDCs which had migrated toward
the medium without CCL21 served as a negative control. The
migration conditions used in this study were pre-optimized
(Supplementary Figure S2).
MSC-EV miRNA Profiling
Total RNA in MSC-EVs was purified using the Total Exosome
RNA and Protein isolation kit (Thermo Fisher Scientific). Total
RNA from the parent MSCs was purified from cell lysates
using the Qiagen RNAeasy mini kit, as per the manufacturer’s
instructions. The concentration and quality of total RNA from
MSC and MSC-EVs was determined using Bioanalyzer 2100
with the RNA 6000 Nano and Pico kits, respectively (Agilent
technologies). At least 2 ng of total RNA were used as input
for the nCounter R© Human miRNA Expression assay V3 kit
(NanoString Technologies). The miRNA expression profiles were
then analyzed using the nSolver software V2.5 (NanoString
Technologies) according to the manufacturer’s instructions.
Samples were normalized to the geometric mean of the 100
miRNAswith the highest counts and amicroRNAwas considered
as differentially expressed when its expression exhibited a fold
increase >1.5 and a p-value <0.05 as determined by the nSolver
software using Student’s t-tests.
Quantitative Real Time PCR
Validation of MSC-EV and MSC miRNA expression profiles
was performed by qRT-PCR. Total RNA extraction and quality
was assessed as aforementioned. The miRNA specific copy
DNA synthesis was carried out using the SensiFASTTM probe
HI-ROX master mix (Bioline) and the Taqman R© primer probe
sets for: hsa-mir-21-5p (5′-UAGCUUAUCAGACUGAUGUUGA-
3′), hsa-miR-223 (5′-UGUCAGUUUGUCAAAUACCCCA-3′),
has-miR142-3p (5′-UGUAGUGUUUCCUACUUUAUGGA-3′),
hsa-miR-126 (5′-UCGUACCGUGAGUAAUAAUGCG-3′) and
U6 snRNA control (5′-GTGCTCGCTTCGGCAGCACATAT
ACTAAAATTGGAACGATACAGAGAAGATTAGCATGGCCCC
TGCGCAAGGATGACACGCAAATTCGTGAAGCGTTCCAT
ATTTT-3′), (all from Thermo Fisher Scientific).
DC Transfection
The miRIDIAN microRNA hsa-miR-21 mimic and the
miRIDIAN microRNA transfection control with Dy547 were
purchased from Dharmacon. The siRNA dried pellets were re-
suspended in RNase free water to a stock solution of 20µM, then
stored at −80◦C. The transfection of DCs was performed based
on a lipid-siRNA transfection method as previously described
(28). Briefly, 3 × 105 CD14+ monocytes were seeded in 24-well
plates in complete media supplemented with 50 ng/ml of GM-
CSF and IL-4. On day 3 of the culture, the lipid-siRNA complexes
were formed by combining 117.5 µls of warm serum-free RPMI
with 3.75 µls of HiPerFect transfectant (Qiagen) and 3.75 µls
of siRNA stock solutions (final concentration of 200 nM). The
lipid-siRNA mixture was incubated for 15–20min at RT with
constant mixing to enhance the formation of the complexes.
125 µls of the lipid-complex were added to one side of a well
of a tilted 24-well plate and day 3 DCs were added directly into
the lipid-siRNA complexes and the plate was gently swirled to
ensure uniform distribution of the lipid-siRNA complexes then
incubated at 37◦C and 5% CO2 for 4 h. The transfection was
then stopped with RPMI supplemented with GM-CSF and IL-4
and cells were kept in culture until day 7 as aforementioned.
Transfection efficiency and viability of the cells was monitored
on days 4, 5, 6, and 7 of DC generation and the effect of miR-21
overexpression on DC maturation and function was assessed.
Statistical Analysis
Unless otherwise stated, all statistical analysis was carried out
using GraphPad Prism version 6 (GraphPad Software). Mann-
Whitney U tests or Student’s t-tests were used to determine
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statistical significance. Differences were considered statistically
significant at a p-value <0.05.
RESULTS
MSC and MSC-EV Characteristics
MSCs were generated from healthy bone marrow aspirates and
expanded in xeno-free conditions. The generated MSCs were
confirmed as being compliant with the ISCT criteria (24) prior
to be used for EV purification (Supplementary Figure S3). MSC-
EV purification yielded an average of 1.16 × 1011 ± 2.95 × 1010
particles/ml, or 432 ± 229 particles/cell (Figure 1A). Purified
MSC-EVs showed a modal size of 152 ± 23 nm (Figure 1B),
and exhibited the expected cup-shaped morphology, as assessed
by TEM (Figure 1C). MSC-EVs positively expressed common
transmembrane proteins enriched in EVs, including CD63, CD9,
and CD81 (Figure 1D).
MSC-EVs Preferentially Target DCs
To identify whether MSC-EVs primarily target DCs or T
cells, PKH26 labeled MSC-EVs were added into the co-culture
of purified T cells and mDCs then visualized the spatial
association of MSC-EVs with DCs and T cells. We found a
predominant association between MSC-EVs and DCs detected
by the fluorescence staining overlap of PKH26 labeled MSC-
EVs (red) and HLA-DR labeled DCs (green). No association
was detected between the labeled MSC-EVs and CD3+ T cells
(Figure 2).
MSC-EVs Impair Antigen Uptake by
Immature DCs
Immature DCs (iDCs) effectively capture and process antigens,
which can be assessed by their uptake of FITC-dextran. Upon DC
maturation following the stimulation with LPS (a TLR4 ligand),
a function switch occurs from antigen capture and processing to
predominantly presenting antigens to T cells (29). As expected,
iDCs showed significantly higher levels of FITC dextran uptake
than the mDCs (p = 0.003). MSC-EV treated iDCs (iDC-EV)
showed a decreased ability to take up FITC dextran (p = 0.012;
Figure 3), suggesting that MSC-EVs can exert a modulatory
effect onDC function by blocking the first step of DCmaturation.
MSC-EVs Alter DC Phenotype and
Function
We next examined the effect of MSC-EV treatment on DC
maturation and activation by assessing their expression of
CD83, CD38, co-stimulatory molecules CD80 and CD86, as
well as HLA-DR. Mature and immature DCs showed expected
high or low levels of all the aforementioned surface markers,
respectively (p < 0.05; Figure 4A). MSC-EV treated mDCs
expressed a markedly reduced expression of CD83, CD38 and co-
stimulatory molecules CD80 compared to the untreated mDCs
(p= 0.009, 0.05, and 0.03, respectively). No significant difference
was detected in the expression of CD86 and HLA-DR between
MSC-EV treated and untreated mDCs (Figure 4A).
Upon LPS stimulation mature DCs secrete high levels of pro-
inflammatory cytokines, IL-6 and IL-12 (30). To verify the impact
that MSC-EVs may have on mature DC cytokine secretion
following LPS stimulation the levels of IL-6, IL-12-p70, IL-
10, and TGF-β were measured in the culture supernatants of
iDCs, mDCs, and MSC-EV treated mDCs. The levels of IL-6
production by MSC-EV treated mDCs was markedly lower than
that secreted by untreated mDCs (p = 0.01) but higher than that
secreted by iDCs (p = 0.03). MSC-EV treated mDCs produced
the IL-12-p70 at a level that was over 100-fold lower than that
produced by untreated mDCs (p = 0.036) but no significant
difference to that produced by iDCs (p > 0.05). Importantly,
MSC-EV treated mDCs showed an increased production of
the anti-inflammatory cytokine TGF-β compared to untreated
mDCs (p = 0.05). No significant difference was observed in IL-
10 production across all DC groups (Figure 4B). To evaluate the
functional effect of MSC-EV treated DCs on T cell responses
we stimulated allogeneic T cells with MSC-EV treated DCs and
measured T cell cytokine secretion and T cell proliferation. The
results showed that T cells stimulated with MSC-EV treated
DCs secreted lower levels of IL-6 and IFN-γ compared to those
co-cultured with untreated DCs (p = 0.05 for both) while no
significant difference was observed in TNFα and IL-2 production
between the two groups (p> 0.05 for both; Figure 4C). However,
MSC-EV treated DCs did not show a suppressive effect on
allogeneic T cell proliferation compared to the T cells stimulated
with untreated mDCs (Figure 4D).
MSC-EVs Impair DC Migration via
Suppression of CCR7 Expression
CCR7 plays an essential role in DC homing to the lymph nodes.
Upon the presence of inflammatory stimuli, DCs mature and
gain CCR7 expression which, by binding to its ligand CCL21 or
CCL19, direct DCs to the lymph nodes for antigen presentation
(31). We evaluated CCR7 expression on mDCs, with or without
MSC-EV treatment, and their ability to migrate toward CCL21
using the transwell system. We detected a 3-fold lower CCR7
expression on MSC-EV treated DCs compared to the untreated
counterpart (p= 0.003, Figure 5A). In addition, MSC-EV treated
DCs showed a significantly reduced migration efficiency toward
CCR7 ligand CCL21 in comparison to untreated DCs (22.4 ±
4.0% and 73.2± 6.4%, respectively; p < 0.0001, Figure 5B).
MSC-EVs Encapsulate Immunomodulatory
microRNAs
To further scrutinize the molecular mechanisms underlying
MSC-EV mediated modulation of DC maturation and function,
we profiled the miRNA contents in MSC-EVs in comparison to
their parent cells using the NanoString technology. High quality
of RNA extracted from MSCs and MSC-EVs was confirmed by
bioanalyzer analysis. MSC-derived RNA showed RNA integrity
numbers (RIN) >7 and exhibited single narrow peaks at the
18 and 28S ribosomal RNA (Figure 6A). MSC-EVs enclosed
only small RNA species with sizes from 25 up to ∼200
nucleotides. No RIN was calculated for MSC-EV derived RNA
due to the absence of the ribosomal RNA peaks (Figure 6B).
The microRNAs in MSCs and MSC-EVs displayed a polarized
distribution as shown by the principal component analysis plot
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FIGURE 1 | Characteristics of MSC-derived EVs. MSC-EVs were isolated from MSC conditioned medium by differential ultracentrifugation. Isolated EVs were
assessed for (A) particle concentration, (B) particle size distribution, and (C) morphology using nanoparticle-tracking analysis and transmission electron microscopy,
respectively. Flow cytometry was used to comfirm the expression of EV signature markers (D). The scale bar represents 100 nm. The error bars represent mean ±
SEM of four independent experiments.
FIGURE 2 | MSC-EVs preferentially target DCs. Representative images from confocal microscopy showing that EV-PKH26+ labeled MSC-EVs (red) are closely
associated with DCs (green). No uptake of MSC-EVs by CD3+ T cells (blue) was detected. The scale bars represent 50 and 20µm.
(Figure 6C). The NanoString microRNA profiling identified 79
microRNAs that were differentially expressed between MSC-
EVs and MSCs. These differentially expressed miRNAs were
presented in a heatmap based on a hierarchical clustering analysis
(Figure 6D). Amongst these 79 miRNAs, 49 were enriched
in MSC-EVs while the remaining 30 were enriched in the
parent cells. MiRNAs with known effect on DC maturation and
function, including miR-21-5p, miR-142-3p, miR-223-3p, and
miR-126-3p, were detected within the top 10 enriched miRNAs
in MSC-EVs (Table 1). These microRNAs were validated using
RT-qPCR in an independent cohort of samples and showed
significantly higher expression levels in MSC-EVs compared
to parent cells (Figure 6E), suggesting a potential selective
packaging of these microRNAs into EVs, which may serve
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FIGURE 3 | MSC-EVs impair antigen uptake by immature DCs. FITC dextran uptake was used to assess antigen uptake by immature, mature and MSC-EV treated
immature DCs. (A) Representative histograms and (B) cumulative data of FITC dextran uptake as assessed by flow cytometry. Pale gray histograms represent isotype
control. Results express mean ± SEM of four independent experiments (*p < 0.005, **p < 0.01).
as a vehicle to deliver the miRNA contents to the target
cells. A detailed list of the 79 differentially expressed miRNAs
detected in MSC-EVs and respective parent cells are provided in
Supplementary Table S1.
Transfection of DCs With miRNA-21-5p
Partially Mimics the Function of MSC-EV
Treated DCs
MicroRNA-21-5p is one of the most enriched miRNAs
enclosed in MSC-EVs (Table 1). Target analysis revealed that
the CCR7 gene can be targeted by miR-21-5p (Figure 7A),
suggesting the enriched miRNA-21-5p in MSC-EV may function
as a potential molecular mechanism underpinning MSC-EV
mediated impairment of DC migration and function. To
confirm this hypothesis, we examined whether overexpression
of miR-21-5p in DCs could recapitulate the effect of MSC-
EV treatment by transfecting DCs with a miR-21-5p mimic
and a fluorescently labeled miRNA scramble on day 3 of DC
generation culture using a lipid based transfection method as
previously reported (28). Post-transfection assessment showed
the highest transfection efficiency at 72 h with comparable
cell viability between transfected and non-transfected cells
(Supplementary Figures S4A–C). Overexpression of miR-21-5p
was confirmed by RT-qPCR compared to the non-transfected
and scramble miRNA controls (p < 0.05; Supplementary
Figure S4D). Functionally, miR-21-5p mimic transfected DCs
exhibited a significant decrease in their migratory capacity
toward CCL21 in comparison to non-transfected and scramble
miRNA transfected controls, with a migration efficiency of 18.25
± 4.43%, 44.75 ± 10.33%, and 44.75 ± 10.76%, respectively
(p < 0.05 for both; Figure 7B). MiR-21-5p mimic transfected
DCs also showed a trend toward a reduction in CCR7 expression
compared to the controls, although a statistical significance was
not achieved (Figure 7C). In addition, a tendency of secreting
lower levels of IL-6 and IL-12p70 was observed in MiR-21-5p
mimic transfected DCs compared to both controls, although
a statistical significance was not reached (p > 0.05 for all;
Supplementary Figure S4E).
DISCUSSION
MSC-EVs have been reported to recapitulate the intrinsic
regenerative and immunomodulatory properties of MSCs (32–
35). So far, little knowledge is available about the influence
of MSC-EVs on DC modulation and associated potential
mechanistic pathway by which MSC-EVs exert their modulatory
effects on DCs.
We have demonstrated for the first time that MSC-EVs are
able to impede DC maturation and modify DC function, in a
similar manner to that previously reported with MSCs (21, 36,
37). Exposure to MSC-EVs has attenuated antigen uptake by
immature DCs and rendered mature DCs with a semi-mature
phenotype after LPS stimulation, characterized by intermediate
level expression of CD83, CD38, and CD80 that was higher
than immature DCs but lower than untreated mature DCs.
This phenotype change was accompanied with a functional
shift in DC cytokine production profile from inflammatory
to immunoregulatory. MSC-EVs have been reported to induce
regulatory macrophage phenotype change and skew their
cytokine production toward a regulatory profile with increased
production of anti-inflammatory cytokines and downregulation
of inflammatory cytokine production (11, 33, 38). A recent
study by Tung et al. (39) also demonstrated that regulatory T
cell-derived EVs (Treg-EVs) induced anti-inflammatory cytokine
secretion by DCs, with an increased IL-10 and decreased
IL-6 production following LPS stimulation (39). It is well-
recognized that regulatory T cells (Tregs) and MSCs share
similar immunomodulatory properties. The research findings
from Treg-EVs tend to corroborate our observations fromMSC-
EVs. The discrepancy in the ability of Treg-EVs and MSC-
EVs to influence the expression of the co-stimulatory molecule
CD80 and the difference in Treg-EV and MSC-EV induced IL-
10 production by DCs endorse the notion that although Tregs
and MSCs share similar immunomodulatory properties they
may exert their modulatory effects on DCs through different
mechanistic pathways.
It is clear that DCs orchestrate the immune system through
both cell-cell contact and cytokine secretion pathways. IL-12
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FIGURE 4 | MSC-EVs modulate DC maturation and cytokine secretion. (A) Cumulative (top) and representative (bottom) data showing expression of surface markers
CD38, CD83, CD80, CD86 and HLA-DR as determined by flow cytometry on immature, mature and MSC-EV treated mature DCs. (B) Cell culture supernatants
collected from iDC, mDC and mDC-EVs were analyzed for the levels of IL-6, IL-12p70, TGF-β and IL-10. (C) Supernatants collected from the co-culture of CD3+ T
cells with either mDCs or mDCs-EVs were analyzed for the levels of IFN-γ, IL-6, TNF-α and IL-2. T cells cultured with medium alone served as a control.
(D) Representative (left) and cumulative (right) data showing allogeneic CD3+ T cell proliferation stimulated with mDCs and mDC-EVs as assessed by flow cytometry
analysis of CFSE dilution. Data represent mean ± SEM of 4–6 independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. ND, not detectable.
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FIGURE 5 | MSC-EVs impair DC migratory via suppression of CCR7 expression (A) Representative histograms (left) and cumulative levels (right) of CCR7 expression
by mDCs and mDC-EVs. Live cells were selected prior to histograms and levels of expression were compared to isotype controls. (B) Migration efficiency of mDCs
and mDC-EVs. Mature DCs migrated toward the medium without CCL21 served as a background control. Results were expressed as mean ± SEM of 4–6
independent experiments. **p < 0.01, ***p < 0.001 and ****p < 0.0001.
and TGF-β play critical roles in shaping immune responses
during antigen presentation and influencing cell-fate decisions
relating to naïve T cell differentiation into the appropriate T
cell subtypes in response to the environment challenge. DCs are
one of the key producers of IL-12, which dominantly target T
cells by inducing T cell IFNγ production mainly through STAT4
(40). Our observation of a decreased IL-12-p70 production by
MSC-EV treated DCs suggests that MSC-EV treated DCs may
skew the balance of Th1 and Th2 effector T cells, in favor
of the latter, as evidenced in our further finding that T cells
stimulated with MSC-EV treated DCs had a markedly reduced
secretion of IFNγ. It is important to confirm the T cell subsets
derived from the naïve T cells stimulated with MSC-EV treated
DCs in future studies, including demonstrating IL-4 and IL-
5 production by T cells stimulated by MSC-EV treated DCs.
TGF-β is an important cytokine playing fundamental roles
in the regulation of immune responses during homeostasis
and disease. In addition to the direct effect on Th1 and
Th2 effector responses, TGF-β promotes immunosuppression
via direct induction of Foxp3 expressing Tregs both in the
thymus and the periphery (41, 42). The potency of MSC-EVs
in inducing Treg production was previously demonstrated in
mouse models of GvHD and type 1 diabetic patients (43–
45). MSC-EVs ameliorated GvHD symptoms and increased
survival in a murine model of GvHD via the induction of
CD4+CD25+FoxP3+ T cells in an APC-mediated pathway
(43). The therapeutic use of MSC-EVs for the treatment of
therapy-refractory GvHD in humans has also been observed
showing that MSC-EV treatment was able to ameliorate GvHD
symptoms with evident inhibition of inflammatory cytokine
secretion (35).
Controversial findings have been reported with regard to
the ability of MSC-EVs to suppress T cell proliferation. MSC-
EVs have induced a significant suppression of the proliferation
of CD3+ T cells stimulated directly with anti-CD3/CD28 in
the absence of DCs (8). Co-cultures of autologous T cells
with MSC-EV conditioned DCs pulsed with a specific auto-
antigen showed no significant reduction in T cell activation
and proliferation when re-challenged with the same antigen
(46). In our study comparable levels of allogeneic T cell
proliferation were observed following the stimulation with either
untreated or MSC-EV treated DCs in vitro, suggesting that
MSC-EVs may influence T cell response predominantly via
skewing T cell cytokine production profile as evidenced in our
observation of a decreased IFNγ and IL-6 secretion by the T
cells stimulated with MSC-EV treated DCs. It is worth noting
that, despite the inability of MSC-EV treated DCs to suppress
T cell proliferation in the in vitro experiment, our finding
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FIGURE 6 | MSC-EVs encapsulate immunomodulatory microRNAs. (A,B) The profile of RNAs derived from MSCs and MSC-EVs as analyzed using Bioanalyzer. (C)
Principal component analysis plot of microRNA profile of MSCs (blue) and MSC-EVs (red). (D) Heatmap showing the 79 differentially expressed microRNAs between
MSCs and MSC-EVs. Heatmap colors represent relative microRNA expression as indicated by the color key, i.e., under-expressed (blue) and over-expressed (red).
Each row is representative of one microRNA and each column one sample. RStudioTM was used to plot the results. (E) RT-qPCR validation of the immunomodulatory
microRNAs enriched in MSC-EVs. The graphs depict relative expression levels conveyed as 2dCT and results were expressed as mean ± SEM of 3 independent
experiments. **p < 0.01.
that MSC-EV treated DCs had decreased CCR7 expression and
reduced ability to migrate toward the CCR7 ligand CCL21
indicates the possibility that MSC-EV treated DCs may be able
to dampen down inflammatory T cell responses in vivo due to
impairedmigration to secondary lymphoid tissues. This notion is
supported by previous observations from murine in vivo models
showing that intravenous administration of MSCs decreased
the number of CCR7 expressing DCs in the draining lymph
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nodes and hindered local antigen priming of CD4+ T cells (22)
Interestingly, in our study when MSC-EVs were added directly
to the co-culture of DCs and allogeneic T cells a diminished
TABLE 1 | Top 10 microRNAs in MSC-EVs.
microRNA Counts SEM
hsa-miR-4454 + hsa-miR-7975 173, 824.7 501.6
hsa-miR-4286 8, 182.4 2.3
hsa-miR-21-5p 6, 957.7 122.5
hsa-miR-223-3p 2, 029.6 0.0
hsa-miR-142-3p 1, 659.4 0.2
hsa-miR-22-3p 1, 631.4 72.3
hsa-miR-29b-3p 1, 378.2 34.6
hsa-miR-630 1, 232.5 4.7
hsa-miR-126-3p 1, 156.7 5.2
has-miR-1260a 675.9 144.4
Top 10 microRNAs are listed according to their expression levels (count number) in MSC-
EVs as detected by the Nanostring miRNA profile (n= 3). Counts represent the geometric
mean of copy numbers detected in each analyzed sample ± SEM.
T cell proliferation was detected (Supplementary Figure S1),
suggesting that MSC-EVs may also exert direct effect on T cells
under certain conditions, as shown in other studies (8, 10).
Although the mechanisms of MSC-EV mediated suppression
of T cell proliferation are not fully understood, published
data suggests that these vesicles induce T cell apoptosis
(11).
One of the most striking phenotype changes in MSC-EV
treated DCs is the reduction in CD38 expression. CD38 is
an ectoenzyme that catalyzes the synthesis of cyclic adenosine
diphosphate ribose, which initiates transmembrane signaling
upon engagement with CD31 (47). It induces the expression
of CD83 and IL-12 production in DCs via NF-κB pathway
(48, 49). CD38 is also laterally associated with CCR7, therefore
an important regulator of DC migration (48). In addition, data
from a murine model showed that CD38−/− immature DCs
are less efficient in taking up antigens (50). Taken together,
MSC-EV mediated suppression of CD38 expression in DCs may
be an initiating upstream event contributing directly to the
reduced phagocytic capacity, decreased CD83 expression and IL-
12 production, as well as impaired CCR7 expression and CCL21
driven migration, as observed in this study. Future studies into
FIGURE 7 | Transfection of DCs with miR-21-5p partially mimics the function of MSC-EV treated DCs. (A) In silico analysis of miR-21-5p targets revealed that this
microRNA directly targets CCR7 and IL12A genes. Targets for miR-21-5p were queried using miRSystems and graphic representations and complementarity
information of miR-21-5p with CCR7 and IL12A genes were obtained from the online database http://www.targetscan.org/vert_72/. (B) Migratory capacity of
non-transfected DCs and DCs transfected with MiR-21-5p mimics or scramble controls, as detected using a transwell system. DCs migrated toward medium without
the chemoattractant served as a background control. (C) CCR7 expression was analyzed by flow cytometry. Live cells were selected prior to histograms and levels of
expression were compared to the isotype control. Results were expressed as mean ± SEM of 4-6 independent experiments. *p < 0.05.
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the relevant molecular signaling pathways may provide further
insight to uncover the complex interactive signaling networks
involved in MSC-EV mediated DC modulation.
Another key novel finding from this study is that microRNAs
enclosed in the MSC-EVs may represent a potential mechanism
by which MSC exert their modulatory role in DCs. Increasing
evidence suggests that MSC-EV enclosed miRNAs are important
effectors for the biological and therapeutic effect of these vesicles
(6, 34, 51, 52). Our study identified four highly enriched
microRNAs with essential roles in DC development and function
in MSC-EVs, including miR-21-5p, miR-142-3p, miR-223-3p,
and miR-126-3p. Based on the miRNA profile of MSC-EVs and
the effect of these vesicles on DC maturation and function, we
performed target analysis using the miRSystem online software
which retrieves both validated and predicted microRNA targets
from multiple online databases (53). The analysis revealed that
miR-223-3p targets the CD83 gene, while miR-142-3p has been
experimentally observed as an inhibitor of IL-6 expression (54).
Recent evidence also showed that Treg-EV enclosed miR-142-
3p can be acquired by DCs resulting in the induction of a
tolerogenic phenotype in DC (38). Moreover, miR-126-3p targets
genes upstream TLR signaling, such as Tsc1, a negative regulator
of the mTOR kinase (55) and miR-29b targets Bcl-2 gene, which
is involved in the maintenance of DC longevity in vivo (56).
MiR-21-5p is one of the most highly expressed microRNAs in
MSC-EVs. It has been experimentally observed to directly target
IL-12A, inhibit IL-12p35 production, as well as indirectly drive
IL-6 degradation, and promote the expression of TGF-β1 and IL-
10 (57–59). MiR-21-5p has also been experimentally observed to
directly target CCR7 gene for degradation. In DCs miR-21 was
shown to have a highly conserved target region in CCR7 3′UTR
and to be significantly down-regulated uponDCmaturation (60).
Lentiviral transfection of DCs with miR-21 has demonstrated a
reduction ofCCR7 expression after LPSmaturation. In our study,
transfection of DCs with miR-21-5p mimics has significantly
diminished DC migration toward the CCR7 ligand CCL21,
accompanied with a tendency toward a decreased CCR7 protein
expression and reduced proinflammatory cytokine production.
Given the high concentration of miR-21-5p detected in MSC-
EVs and the critical roles it plays in DC function, it is plausible to
hypothesize that delivery of miR-21-5p via secreted EVs may be
an important potential mechanistic pathway underpinning MSC
mediated modulatory effects on DCs. However, further studies
would be needed to demonstrate the direct delivery of MSC-
EV enclosed miR-21-5p to DCs and the impact of other relevant
microRNAs, as well as the bioactive factors beyond microRNAs,
should be duly recognized. Furthermore, MSCs secrete a
heterogeneous population of vesicles. It is possible that distinct
vesicles purified from MSC conditioned media exhibit distinct
immunomodulatory properties (61, 62). However, assessing the
functionality of EV subpopulations may not be succeeded until
better and more high throughput purification methodology is
developed for EV purification.
In summary, our findings suggest that MSC-EVs are able
to recapitulate MSC mediated DC modulation and MSC-
EV enclosed microRNAs may represent a potential novel
mechanism through which MSCs modulate DC functions. As
MSCs are currently used in clinical trials to treat numerous
immune dysregulation associated diseases, our data provide
novel evidence to inform potential future application of MSC-
EVs as a cell-free therapeutic agent.
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